The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Human Insulin from Recombinant DNA Technology
Abstract
Human insulin produced by recombinant DNA technology is the first commercial health care product derived from this technology. Work on this product was initiated before there were federal guidelines for large-scale recombinant DNA work or commercial development of recombinant DNA products. The steps taken to facilitate acceptance of large-scale work and proof of the identity and safety of such a product are described. While basic studies in recombinant DNA technology will continue to have a profound impact on research in the life sciences, commercial applications may well be controlled by economic conditions and the availability of investment capital.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Construction of Biologically Functional Bacterial Plasmids In Vitro
Cohen, S. N., Chang, A. C. Y., Boyer, H. W., & Helling, R. B. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.11.3240 · Cited by 1,802
Reddy, E. P., Reynolds, R. K., Santos, E., & Barbacid, M. (1982) · Nature · doi:10.1038/300149a0 · Cited by 1,391
Jackson, D. A., Symons, R. H., & Berg, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.10.2904 · Cited by 778
Potential Biohazards of Recombinant DNA Molecules
Berg, P., Baltimore, D., Boyer, H. W., Cohen, S. N., Davis, R. W., Hogness, D. S., Nathans, D., Roblin, R., Watson, J. D., Weissman, S., et al. (1974) · Science · doi:10.1126/science.185.4148.303 · Cited by 402
Asilomar Conference on Recombinant DNA Molecules
Berg, P., Baltimore, D., Brenner, S., Roblin, R. O., & Singer, M. F. (1975) · Science · doi:10.1126/science.1056638 · Cited by 217
Chemical, Physical, and Biologic Properties of Biosynthetic Human Insulin
Chance, R. E., Kroeff, E. P., Hoffmann, J. A., et al. (1981) · Diabetes Care · doi:10.2337/diacare.4.2.147 · Cited by 117
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Development and Challenges of Antimicrobial Peptides for Therapeutic Applications
Chen, C. H., & Lu, T. K. (2020) · Antibiotics · doi:10.3390/antibiotics9010024 · Cited by 598
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
A Review of the Microbial Production of Bioactive Natural Products and Biologics
Pham, J. V., Yilma, M. A., Feliz, A., Majid, M. T., Maffetone, N., Walker, J. R., Kim, E., Cho, H. J., Reynolds, J. M., Song, M. C., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01404 · Cited by 565
Recent advances in nanomaterials for water protection and monitoring
Das, R., Vecitis, C. D., Schulze, A., Cao, B., Ismail, A. F., Lu, X., Chen, J., & Ramakrishna, S. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00921b · Cited by 552
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
“Click” reactions: a versatile toolbox for the synthesis of peptide-conjugates
Tang, W., & Becker, M. L. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00139g · Cited by 376
Recombinant pharmaceuticals from microbial cells: a 2015 update
Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0437-3 · Cited by 339
Peptide-based drug discovery: Current status and recent advances
Sharma, K., Sharma, K. K., Sharma, A., & Jain, R. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103464 · Cited by 313
Particle engineering techniques for inhaled biopharmaceuticals
Shoyele, S. A., & Cawthorne, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.010 · Cited by 301
Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.36 · Cited by 287
Insulin delivery systems combined with microneedle technology
Jin, X., Zhu, D. D., Chen, B. Z., Ashfaq, M., & Guo, X. D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.011 · Cited by 275
Structure of the insulin receptor–insulin complex by single-particle cryo-EM analysis
Scapin, G., Dandey, V. P., Zhang, Z., Prosise, W., Hruza, A., Kelly, T., Mayhood, T., Strickland, C., Potter, C. S., & Carragher, B. (2018) · Nature · doi:10.1038/nature26153 · Cited by 259
Molecular origins of surfactant-mediated stabilization of protein drugs
Lee, H. J., McAuley, A., Schilke, K. F., & McGuire, J. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.015 · Cited by 258
The evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia
De León, D. D., & Stanley, C. A. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.06.005 · Cited by 63
Current PAT Landscape in the Downstream Processing of Biopharmaceuticals
Sathiyapriyan, P., Mukherjee, S., Vogel, T., Essen, L., Boerema, D., Vey, M., & Kalina, U. (2025) · Analytical Science Advances · doi:10.1002/ansa.70013 · Cited by 45
A historical perspective on the interactions of insulin at the blood‐brain barrier
Rhea, E. M., & Banks, W. A. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12929 · Cited by 34
Metadata
- Authors
- Johnson, I. S.
- Venue
- Science
- Published
- 1983-02-11
- Volume
- 219
- Issue
- 4585
- Pages
- 632-637
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006512810
- Cited by
- 401
- References
- 6
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.